Albemarle Longevity Class I
September 2026

Marketing Communication

About Albemarle Asset Management

Founded in London in 2003. Companies house incorporation filing, 25 July 2003. The company provides individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our expertise enables a diverse offering of investment instruments and strategies.

Fund Objective


Albemarle Longevity Fund is a sub-fund of Albemarle Funds Plc, an open-ended investment company with variable capital incorporated in Ireland. The fund objective is to achieve long term capital appreciation by investing in the Italian equity market. Please refer to page 2 for key risks. The fund is actively managed.

Performance: past returns doesn't predict future returns


	YTD	1M	6M	1YR	Inception
Fund	-2.42%	-2.55%	4.25%	-0.70%	-11.58%

	Best Mth	Worst Mth	CAGR	Volt.	Sharpe R.
Fund	-24.55%	9.89%	-1.83%	14.24%	-0.19

Chart Performance *



Returns *



Fund Information

Company	Albemarle Funds Plc
Investment Manager	Albemarle Asset Management Ltd
Bloomberg	ATGASII ID
ISIN	IE00B50NJG20
Inception	05/02/2020
Currency	EUR
Fund Manager	Albemarle Asset Management Ltd
Management Fees	0.75% p.a. (Class I)
Benchmark	N/A
Performance Fees	15% of the amount by which the net asset value exceeds the high water mark
NAV	Daily
Cut-Off	T-1 before 1pm Irish Time
Settlement date f	T+2 Irish Business Days
Settlement date f	T+2 Irish Business Days
Domicile	Ireland
Auditors	Grant Thornton
Depositary	Northern Trust Fiduciary Services (Ireland) Ltd
Category	UCITS V

Important Information

This document is for the use of Institutional and Professional investors only. Investor rights are available at the website: albemarleasset.com in both Italian and English. The UCITS management company and the AIFM may cease cross-border marketing at any time.

Source: Bloomberg

** Please note the strategy of the fund changed on February 5th, 2020*

Different Share Classes

Class	NAV	YTD	1M	6M	1YR	Since Inception	Inception Date	ISIN	Management Fee
A	Daily	-2.96%	-2.61%	3.86%	-13.96%	34.82%	05/02/2020	IE00B3BM9X16	1.5% p.a.


Albemarle Asset Management Limited, 21 Upper Brook Street, London W1K 7PY

Tel: +44(0)2072907730 - www.albemarleasset.com - albemarlefunds@albemarleasset.com

ALBEMARLE
ASSET MANAGEMENT

Albemarle Longevity Class I
September 2026


Sector Breakdown Net Exposure (%)




Top Holdings

ASTRAZENECA PLC	2.92%
ECKERT & ZIEGLER SE	2.91%
SANLORENZO SPA/AMEGLIA	2.82%
NOVARTIS AG-REG	2.80%
GENMAB A/S	2.78%
Total	**14.23%**

Asset Allocation Exposure (%)



Country Breakdown Net Exposure (%)



Commentary

The Fund posted a negative performance in September, in line with the main European equity indexes. The main positive contributors were Tecan, Genmab, Sonova, El.En and Qiagen. Tecan rose as the stock of the Swiss laboratory automation company continued to rally also thanks to some analysts lifting their price target on the stock. El.En rose as the Italian medical laser equipment company posted convincing Q2 results with revenues accelerating to +11.4% YoY and EBIT materially expectations thanks to a favourable product mix and strong operating leverage, triggering some earnings upgrades on underlying basis. Qiagen rose as news emerged that the molecular testing company is attracting interest from multiple private equity firms, including KKR, EQT, Advent, TPG, and Bain Capital. The main detractors to the Fund performance had been Trigano, Novo Nordisk, EssilorLuxottica, BB Biotech and Alcon. Trigano fell as the French motorhome company released Q4 sales slightly (c. -2%) below consensus estimates and delivered an outlook of stable performance for H1 2026/2027 which fell below analysts expectations which were pointing to single digit growth. EssilorLuxottica underperformed as the broader CAC40 and European consumer sector were weak in September, moreover the company was also penalized by continuing governance tensions around the Del Vecchio family, fading optimism around smart-glasses potential, and few analysts downgrades. The main trades executed had been the sale of Siegfried, Diasorin and Stratec.

Important Information and Key Risks: please refer to the KIID and prospectus for full risk details

Investing in the Fund involves material risks, including equity market risks, sector concentration, currency and liquidity risks; the capital invested and any income may rise or fall, and investors could lose the full amount invested, and the Fund may lose value. This information is communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material does not constitute a recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. This can only be distributed to persons who are Professional Clients or Eligible Counterparties, not intended for the general public. Returns expressed in EUR may rise or fall for investors whose local currency is different. You may not get back the amount invested. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read alongside the fund's prospectus (the prospectus and KID are available in English) or supplement documentation before making an investment decision. If you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.

Albemarle Asset Management Limited, 21 Upper Brook Street, London W1K 7PY

Tel: +44(0)2072907730 - www.albemarleasset.com - albemarlefunds@albemarleasset.com